Drug Profile
Research programme: small molecule respiratory disorder therapeutics - Axikin Pharmaceuticals
Alternative Names: AXP-AO; AXP-D; AXP-ELatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Bayer HealthCare
- Developer Axikin Pharmaceuticals
- Class Small molecules
- Mechanism of Action CCR3 receptor antagonists; G protein-coupled receptor antagonists; Immunosuppressants; Inflammation mediator inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Allergic asthma; Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Allergic-asthma in USA (PO)
- 04 Nov 2017 No recent reports of development identified for research development in Asthma in USA
- 04 Nov 2017 No recent reports of development identified for research development in Chronic-obstructive-pulmonary-disease in USA